Indaptus Therapeutics, Inc. (INDP)

NASDAQ: INDP · IEX Real-Time Price · USD
1.90
+0.09 (4.97%)
At close: Mar 24, 2023, 4:00 PM
1.94
+0.04 (2.11%)
After-hours: Mar 24, 2023, 4:00 PM EDT
4.97%
Market Cap 15.96M
Revenue (ttm) n/a
Net Income (ttm) -14.32M
Shares Out 8.40M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,414
Open 1.83
Previous Close 1.81
Day's Range 1.80 - 1.90
52-Week Range 1.25 - 4.25
Beta n/a
Analysts Buy
Price Target 13.26 (+597.9%)
Earnings Date May 11, 2023

About INDP

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 202... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INDP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for INDP stock is "Buy." The 12-month stock price forecast is $13.26, which is an increase of 597.90% from the latest price.

Price Target
$13.26
(597.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Indaptus Therapeutics to Present at the Investor Summit Conference

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today a...

4 days ago - GlobeNewsWire

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of ...

1 week ago - GlobeNewsWire

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative thera...

1 week ago - GlobeNewsWire

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative thera...

1 week ago - GlobeNewsWire

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

First Dose Initial Side-Effect Profile Consistent with Expected Outcome First Dose Initial Side-Effect Profile Consistent with Expected Outcome

2 weeks ago - GlobeNewsWire

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

1 month ago - GlobeNewsWire

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

1 month ago - GlobeNewsWire

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

3 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company Remain s On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022

4 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at the LD Micro Main Event XV

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micr...

5 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th A...

7 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20

8 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will...

10 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will...

10 months ago - GlobeNewsWire

Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?

Indaptus Therapeutics (INDP) stock is soaring higher on Thursday following an update from the U.S. Food and Drug Administration (FDA). The post Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?

11 months ago - InvestorPlace

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Co...

11 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will p...

11 months ago - GlobeNewsWire

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Announces Submission of Investigational New Drug (IND) Application for Decoy20

11 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended December ...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Offic...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate i...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer

Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience

1 year ago - GlobeNewsWire

Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the third quarter ended September 30, 2021 a...

1 year ago - GlobeNewsWire

Maxim Upgrades Indaptus Therapeutics To Buy

Maxim analyst has upgraded Indaptus Therapeutics Inc (NASDAQ: INDP) to Buy from Hold with a $16 price target, an upside of over 100%. Analyst Jason McCarthy says, Indaptus is leveraging the ability of...

1 year ago - Benzinga